Buscar
Adaptimmune Therapeutics PLC
ADAPAñadir a la lista de seguimiento
0.055USD
0.0000.00%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
10.34MCap. mercado
PérdidaP/E TTM
Más Datos de Adaptimmune Therapeutics PLC Compañía
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Información de Adaptimmune Therapeutics PLC
Símbolo de cotizaciónADAP
Nombre de la empresaAdaptimmune Therapeutics PLC
Fecha de salida a bolsaMay 06, 2015
Director ejecutivoRawcliffe (Adrian George)
Número de empleados506
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 06
Dirección60 Jubilee Avenue
CiudadABINGDON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited Kingdom
Código postalOX14 4RX
Teléfono441235430000
Sitio Webhttps://www.adaptimmune.com/
Símbolo de cotizaciónADAP
Fecha de salida a bolsaMay 06, 2015
Director ejecutivoRawcliffe (Adrian George)
Ejecutivos de Adaptimmune Therapeutics PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kristen M. Hege, M.D.
Dr. Kristen M. Hege, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Andrew Allen, M.D., Ph.D.
Dr. Andrew Allen, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Priti Hegde, Ph.D.
Dr. Priti Hegde, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Adaptimmune Therapeutics PLC?
Los cinco principales accionistas de Adaptimmune Therapeutics PLC son: Dr. Garry E. Menzel, Ph.D.
¿Cuántas instituciones poseen acciones de Adaptimmune Therapeutics PLC (ADAP)?
A fecha de 2026Q1, 159 instituciones poseen acciones de Adaptimmune Therapeutics PLC, con un valor de mercado combinado de aproximadamente 1.79M, lo que representa el 0.67% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -156325066.00.